Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?

Annales de dermatologie et de venereologie - 1 Sept 2021

Funck-Brentano E, Malissen N, Roger A, Lebbé C, Deilhes F, Frénard C, Dréno B, Meyer N, Grob J-J, Tétu P, Saiag P

Abstract excerpt

Treatment of patients with melanoma has considerably improved over the past decade and more recently with adjuvant therapies for patients with American Joint Committee on Cancer (AJCC) stage III (loco-regional metastases) or IV (distant metastases) totally resected melanoma, in order to prevent recurrence. In the adjuvant setting, two options are available to patients with BRAFV600-mutant AJCC stage III totally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Nivolumab

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 33579557
DOI: 10.1016/j.annder.2020.11.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?PMID 33579557Read ↗

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.Semantic proximity Read ↗

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Semantic proximity Read ↗

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Semantic proximity Read ↗

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?Semantic proximity Read ↗

How to treat BRAF mutant metastatic melanoma?Semantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.